1,096 results on '"Sampson, John H."'
Search Results
52. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
53. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
54. Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
55. Supplementary Table 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
56. Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery
57. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma
58. Subcutaneous Vaccination with Irradiated, Cytokine-Producing Tumor Cells Stimulates CD8$^{+}$ Cell-Mediated Immunity against Tumors Located in the ``Immunologically Privileged" Central Nervous System
59. Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors
60. Contributors
61. Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial
62. Defining the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases: Results of a Randomized Trial
63. Vaccine-based immunotherapeutic approaches to gliomas and beyond
64. The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial
65. Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside
66. Chapter 9 - Drug testing: translating a novel immunotherapeutic from bench to bedside
67. Reply to ‘Assembling the brain trust: the multidisciplinary imperative in neuro-oncology’
68. Immunotherapy for High-Grade Gliomas
69. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
70. Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy
71. Immunotherapy of Central Nervous System Tumors : Contemporary Cancer Research
72. Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses
73. Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.
74. A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).
75. A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.
76. Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial
77. Radiotherapy and Radiosurgery for Tumors of the Central Nervous System
78. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
79. Biological Principles of Brain Tumor Immunotherapy
80. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
81. Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
82. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
83. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma
84. Prospects of immune checkpoint modulators in the treatment of glioblastoma
85. Peptide vaccines for the treatment of glioblastoma
86. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
87. The Use of Motor Mapping to Aid Resection of Eloquent Gliomas
88. Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas
89. Targeting miR-23a in [CD8.sup.+] cytotoxic T lymphocytes prevents tumor-dependent immunosuppression
90. Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy
91. Cytokine-Based Gene Therapy for Brain Tumors
92. Just Say 'Charge It!'
93. A comprehensive outlook on intracerebral therapy of malignant gliomas
94. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
95. Validation of an Online Calculator to Predict Short-term Postoperative Outcomes in Patients with Metastatic Brain Tumors
96. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
97. Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study
98. A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model
99. Alternating Electric Fields for the Treatment of Glioblastoma
100. Clinical Applications of a Peptide-Based Vaccine for Glioblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.